Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SJP-0132
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
Details : SJP-0132 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : SJP-0132
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Eyenovia
Deal Size : Undisclosed
Deal Type : Collaboration
Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment
Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Eyenovia
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Novaliq
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 13, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Novaliq
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : 14-C SJP-0008
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects
Details : 14-C SJP-0008 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : 14-C SJP-0008
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brimonidine Tartrate,Brinzolamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.
Product Name : Ailamide
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Brimonidine Tartrate,Brinzolamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable